Lifevantage Corp Files 10-Q for Period Ending March 31, 2024

Ticker: LFVN · Form: 10-Q · Filed: May 2, 2024 · CIK: 849146

Lifevantage Corp 10-Q Filing Summary
FieldDetail
CompanyLifevantage Corp (LFVN)
Form Type10-Q
Filed DateMay 2, 2024
Risk Levellow
Pages15
Reading Time19 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: Lifevantage Corp, 10-Q, Quarterly Report, Financials, SEC Filing

TL;DR

<b>Lifevantage Corp filed its Q3 2024 10-Q report on May 2, 2024, detailing financial performance for the period ending March 31, 2024.</b>

AI Summary

Lifevantage Corp (LFVN) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Lifevantage Corp filed a 10-Q report for the period ending March 31, 2024. The filing covers the third quarter of fiscal year 2024. The company's fiscal year ends on June 30. The filing was made on May 2, 2024. Lifevantage Corp is in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking Lifevantage Corp, this filing contains several important signals. This 10-Q filing provides investors with the latest quarterly financial data, including revenue, net income, and balance sheet information, crucial for assessing the company's current performance and future prospects. Understanding the company's financial health and operational status as of March 31, 2024, is vital for making informed investment decisions regarding Lifevantage Corp.

Risk Assessment

Risk Level: low — Lifevantage Corp shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not appear to contain any immediately alarming or unusual disclosures based on the provided header information.

Analyst Insight

Review the detailed financial statements and management discussion within the full 10-Q filing to understand Lifevantage Corp's performance trends and outlook.

Key Numbers

  • 2024-03-31 — Period End Date (Conformed Period of Report)
  • 2024-05-02 — Filing Date (Filed as of date)
  • 2024 Q3 — Fiscal Quarter (Filing details)

Key Players & Entities

  • Lifevantage Corp (company) — Filer
  • 2024-03-31 (date) — Conformed Period of Report
  • 2024-05-02 (date) — Filed as of date
  • 2834 (industry_code) — Standard Industrial Classification
  • 001-35647 (cik) — SEC File Number

FAQ

When did Lifevantage Corp file this 10-Q?

Lifevantage Corp filed this Quarterly Report (10-Q) with the SEC on May 2, 2024.

What is a 10-Q filing?

A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by Lifevantage Corp (LFVN).

Where can I read the original 10-Q filing from Lifevantage Corp?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Lifevantage Corp.

What are the key takeaways from Lifevantage Corp's 10-Q?

Lifevantage Corp filed this 10-Q on May 2, 2024. Key takeaways: Lifevantage Corp filed a 10-Q report for the period ending March 31, 2024.. The filing covers the third quarter of fiscal year 2024.. The company's fiscal year ends on June 30..

Is Lifevantage Corp a risky investment based on this filing?

Based on this 10-Q, Lifevantage Corp presents a relatively low-risk profile. The filing is a standard quarterly report (10-Q) and does not appear to contain any immediately alarming or unusual disclosures based on the provided header information.

What should investors do after reading Lifevantage Corp's 10-Q?

Review the detailed financial statements and management discussion within the full 10-Q filing to understand Lifevantage Corp's performance trends and outlook. The overall sentiment from this filing is neutral.

How does Lifevantage Corp compare to its industry peers?

Lifevantage Corp operates in the Pharmaceutical Preparations sector, which involves the manufacturing and distribution of drugs and medicines.

Are there regulatory concerns for Lifevantage Corp?

As a publicly traded company, Lifevantage Corp is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of quarterly reports (10-Q).

Industry Context

Lifevantage Corp operates in the Pharmaceutical Preparations sector, which involves the manufacturing and distribution of drugs and medicines.

Regulatory Implications

As a publicly traded company, Lifevantage Corp is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of quarterly reports (10-Q).

What Investors Should Do

  1. Analyze the revenue and profitability trends for the quarter ending March 31, 2024.
  2. Examine the balance sheet for changes in assets, liabilities, and equity.
  3. Review any disclosures regarding operational or strategic developments mentioned in the Management's Discussion and Analysis section.

Key Dates

  • 2024-03-31: Period End Date — End of the reporting quarter for the 10-Q filing.
  • 2024-05-02: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This is the initial analysis of the 10-Q filing for the period ending March 31, 2024. Comparative data from previous filings would be needed for a full 'vs last filing' analysis.

Filing Stats: 4,641 words · 19 min read · ~15 pages · Grade level 19.5 · Accepted 2024-05-02 16:05:20

Key Financial Figures

  • $0.0001 — b) of the Act: Common Stock, par value $0.0001 LFVN The Nasdaq Stock Market LLC Title

Filing Documents

Financial Information

PART I. Financial Information 5

Financial Statements

Item 1. Financial Statements: 5 Condensed Consolidated Balance Sheets (unaudited) 5 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) 6 Condensed Consolidated Statement of Stockholders' Equity (unaudited) 7 Condensed Consolidated Statements of Cash Flows (unaudited) 9 Notes to Condensed Consolidated Financial Statements (unaudited) 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 26

Controls and Procedures

Item 4. Controls and Procedures 27

Other Information

PART II. Other Information 27

Legal Proceedings

Item 1. Legal Proceedings 27

Risk Factors

Item 1A. Risk Factors 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 28

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 28

Other Information

Item 5. Other Information 28

Exhibits

Item 6. Exhibits 28

Financial Information

PART I. Financial Information

Financial Statements

Item 1. Financial Statements LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) March 31, 2024 June 30, 2023 (In thousands, except per share data) ASSETS Current assets Cash and cash equivalents $ 17,377 $ 21,605 Accounts receivable 2,135 1,612 Income tax receivable 360 241 Inventory, net 15,162 16,073 Prepaid expenses and other 2,763 4,753 Total current assets 37,797 44,284 Property and equipment, net 8,349 9,086 Right-of-use assets 9,382 8,738 Intangible assets, net 356 455 Deferred income tax asset 4,927 2,991 Other long-term assets 496 569 TOTAL ASSETS $ 61,307 $ 66,123 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 6,954 $ 3,505 Commissions payable 6,093 6,651 Income tax payable 772 — Lease liabilities 1,675 1,521 Other accrued expenses 6,981 7,932 Total current liabilities 22,475 19,609 Long-term lease liabilities 11,852 11,566 Other long-term liabilities 211 299 Total liabilities 34,538 31,474 Commitments and contingencies - Note 7 Stockholders' equity Preferred stock — par value $ 0.0001 per share, 5,000 shares authorized, no shares issued or outstanding — — Common stock — par value $ 0.0001 per share, 40,000 shares authorized and 12,688 and 12,622 issued and outstanding as of March 31, 2024 and June 30, 2023, respectively 1 1 Additional paid-in capital 136,198 134,314 Accumulated deficit ( 107,709 ) ( 98,305 ) Accumulated other comprehensive loss ( 1,721 ) ( 1,361 ) Total stockholders' equity 26,769 34,649 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 61,307 $ 66,123 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Three Months Ended March 31, Nine Months Ended March 31, 2024 2023 2024 2023 (In thousands, except per share data) Revenue, net $ 48,245 $

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.